184 related articles for article (PubMed ID: 18639771)
1. Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia.
Miura S; Saku K
J Cardiol; 2008 Aug; 52(1):1-6. PubMed ID: 18639771
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
5. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
6. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
7. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
8. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
9. Ezetimibe in diabetes: more than cholesterol lowering?
Sarigianni M; Katsiki N; Mikhailidis DP
Curr Med Res Opin; 2010 Oct; 26(10):2517-20. PubMed ID: 20843163
[TBL] [Abstract][Full Text] [Related]
10. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
11. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
12. Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia.
Kashiwabara Y; Kobayashi Y; Koba S; Kohyama N; Ohbayashi M; Murayama JI; Hirano T; Kobayashi Y; Yamamoto T
J Clin Pharm Ther; 2014 Oct; 39(5):551-4. PubMed ID: 24861377
[TBL] [Abstract][Full Text] [Related]
13. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe.
Ziajka PE; Reis M; Kreul S; King H
Am J Cardiol; 2004 Mar; 93(6):779-80. PubMed ID: 15019893
[TBL] [Abstract][Full Text] [Related]
14. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
Meyers CD; Moon YS; Ghanem H; Wong ND
Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
[TBL] [Abstract][Full Text] [Related]
15. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
Ahmed MH; Byrne CD
Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342
[TBL] [Abstract][Full Text] [Related]
17. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
18. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
[TBL] [Abstract][Full Text] [Related]
19. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.
Mascitelli L; Pezzetta F; Goldstein MR
Arch Med Res; 2010 Nov; 41(8):649-50. PubMed ID: 21199735
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe in heart transplantation: initial experience.
Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Agüero J; Sánchez-Lazaro I; Ortiz V; Salvador A
Transplant Proc; 2007 Sep; 39(7):2389-92. PubMed ID: 17889199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
